Several plants have been studied to find their efficacy and anti-cancer activity in various cancers by synthesizing organic metal nanoparticles. However, usage of Semecarpus anacardium (SA) and production of green synthesized nanoparticles have not been exposed. In our study we have focused on synthesizing silver nanoparticles using the nut extracts from SA. Characterization studies including UV-Visible spectrophotometry have confirmed the silver nanoparticle formation at 412 nm using 0.1 mM and 427 nm using 0.2 mM AgNPs. Particle size was recorded at 1.4 nm confirming their effectivity and zeta potential studies confirmed the respective charge of -38.6 mV of the particle. Anti-microbial activity was shown against gram negative bacteria. MTT assay studies confirmed the anti-cancer activity against ovarian cancer cell line, PA-1. These results depict the excellent cytotoxic effect on the PA-1 ovarian cancer cell line, with an IC50 value of 250 μg/ml. Flow cytometry studies confirmed that SA methanolic nut extracts inhibited cell cycle at G0/G1 phase and induced apoptosis. Taken together, we are confirming that SA methanolic extracts have anti-cancer properties against ovarian cancer cell line, PA-1.

Head and neck squamous cell carcinoma (HNSCC) continues to pose a major global health challenge, with over 600,000 new cases diagnosed annually and persistently poor survival outcomes despite advances in surgery, radiotherapy, and immunotherapy. Growing evidence implicates metabolic reprogramming, including enhanced glycolysis, glutaminolysis, lipid synthesis, and one-carbon/redox flux as a central driver of HNC initiation, progression, and therapy resistance. In contrast, metabolic crosstalk within the hypoxic, acidic tumor microenvironment (TME) further shapes immune evasion and stromal support. Recent innovations in mass spectrometry platforms (LC-MS, GC-MS, NMR) have attracted attention in clinical therapeutics, and spatial metabolomics imaging techniques now enable high-resolution in situ mapping of metabolites, revealing intratumoral heterogeneity and offering new insights into tumor-immune–stromal interactions and potential biomarkers for precision oncology. In this review, we integrate critical methodological considerations from sample collection and data-analysis workflows to analytical pitfalls with a balanced, pathway-focused analysis of HNSCC dysmetabolism, examine tumor immune stromal metabolic interactions, and highlight translational opportunities through emerging biomarkers, targeted inhibitors, and cutting-edge approaches such as single-cell and AI-driven metabolomics to chart a roadmap toward precision oncology for HNSCC.